HAMPTON, N.J., Feb. 13, 2015 -- Bellerophon Therapeutics announced today the pricing of its initial public offering of 5,000,000 shares of common stock at a public offering price of $12.00 per share, before underwriting discounts. All of the shares in the offering are being sold by Bellerophon. In addition, Bellerophon has granted the underwriters an option to purchase up to 750,000 additional shares of common stock at the public offering price, less the underwriting discount. Bellerophon's common stock has been approved for listing on the NASDAQ Global Market and is expected to begin trading under the ticker symbol "BLPH" on February 13, 2015. The offering is expected to close on February 19, 2015, subject to customary closing conditions.
Leerink Partners LLC and Cowen and Company, LLC are acting as joint book-running managers for the offering. SunTrust Robinson Humphrey, Inc. and FBR Capital Markets & Co. are acting as co-managers.
A registration statement relating to the securities being sold in this offering has been filed with and declared effective by the Securities and Exchange Commission. The offering is being made only by means of a prospectus. A copy of the prospectus may be obtained from Leerink Partners LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, or by email at firstname.lastname@example.org, or by phone at (800) 808-7525 FREE, ext. 6124, or from Cowen and Company, LLC, c/o Broadridge Financial Services, Attention: Prospectus Department, 1155 Long Island Avenue, Edgewood, NY 11717 or by calling 631-274-2806, or by faxing 631-254-7140.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state or jurisdiction.
Bellerophon Therapeutics is a clinical-stage biotherapeutics company focused on developing innovative therapies at the intersection of drugs and devices that address significant unmet medical needs in the treatment of cardiopulmonary and cardiac diseases. Two of the company's product candidates are based on its proprietary pulsatile nitric oxide delivery device, INOpulse, one for the treatment of pulmonary arterial hypertension and a second for the treatment of pulmonary hypertension associated with chronic obstructive pulmonary disease. Bellerophon's other program is bioabsorbable cardiac matrix, or BCM, which is being developed for the prevention of cardiac remodeling and subsequent chronic heart failure following acute myocardial infarction, commonly known as a heart attack.(www.bellerophon.com)
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/bellerophon-therapeutics-announces-pricing-of-its-initial-public-offering-300035861.html